At a glance
ClinicalIndex Comparison RecordPhase 2Completed· 344 enrolled
Drug / intervention
PF-06700841 +1 moredrug
Likely dose
Not stated in record
Structured eligibility isn't available for this trial yet — see the full criteria in the Eligibility tab below.
Standardized by ClinicalIndex from the ClinicalTrials.gov record · verify against the source.
A PHASE 2B, RANDOMIZED, DOUBLE BLIND, VEHICLE CONTROLLED, PARALLEL-GROUP, DOSE RANGING STUDY TO ASSESS EFFICACY, SAFETY, TOLERABILITY AND PHARMACOKINETICS OF PF-06700841 TOPICAL CREAM APPLIED ONCE OR TWICE DAILY FOR 12 WEEKS IN PARTICIPANTS WITH MILD TO MODERATE CHRONIC PLAQUE PSORIASIS
In Brief
A Phase 2 clinical trial evaluating PF-06700841 and Vehicle (Placebo) for Psoriasis. Completed, enrolled 344 participants across 79 sites in 10 countries.
Detailed Summary
This is a Phase 2b, randomized, double blind, vehicle controlled, parallel group, multicenter study in participants with mild to moderate plaque psoriasis. The duration of study participation will be approximately 22 weeks, including up to a 6 week screening period, 12 week treatment period, and approximately 4 week follow up period. Approximately 280 participants are planned to be randomized into the study.
Study Details
Study Typeinterventional
Allocation--
Masking--
Primary Purpose--
ConditionsPsoriasis
CountriesAustralia, Bulgaria, Canada, Denmark, Germany, Hungary, Japan, Latvia, Poland, United States
Collaborators--
Timeline
Phase 2CompletedFinished
20192020202120222023202420252026
First PostedFeb 2019
Enrollment StartApr 2019
Primary CompletionApr 2021
TodayJul 2026
First PostedFeb 21, 2019
Enrollment StartApr 8, 2019
Primary CompletionApr 20, 2021
TodayJul 2, 2026
Enrollment to primary: 2.0 yearsPosted 7.4 years ago
Interventions
PF-06700841drug
PF-06700841 topical cream
Vehicle (Placebo)drug
Vehicle topical cream